Neurotech International (CHIA:NTI) - Aandelenkoers, Nieuws & Analyse

NTI Overzicht aandelen

NTI fundamentele analyse
Sneeuwvlok Score
Waardering	1/6
Toekomstige groei	2/6
Prestaties in het verleden	0/6
Financiële gezondheid	6/6
Dividenden	0/6

Beloningen

De omzet zal naar verwachting met 44.67% per jaar groeien

Risicoanalyse

Momenteel verlieslatend en er wordt niet verwacht dat dit de komende 3 jaar winstgevend zal worden.

Aandeelhouders zijn het afgelopen jaar verwaterd

Heeft geen betekenisvolle marktkapitalisatie ( A$63M )

Heeft geen zinvolle omzet ( A$3M )

Neurotech International Limited Concurrenten

CurveBeam AI

ASX:CVB

AU$41.4m

Micro-X

ASX:MX1

AU$39.0m

CardieX

ASX:CDX

AU$35.3m

SomnoMed

ASX:SOM

AU$60.5m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Neurotech International
Historische aandelenkoersen
Huidige aandelenkoers	AU$0.061
52 Week Hoogtepunt	AU$0.13
52 Week Laag	AU$0.048
Bèta	1.48
11 maand verandering	12.96%
3 maanden verandering	-14.08%
1 Jaar Verandering	10.91%
33 jaar verandering	-7.58%
5 jaar verandering	238.89%
Verandering sinds IPO	-75.10%

Recent nieuws en updates

Recent updates

Rendement voor aandeelhouders

	NTI	AU Medical Equipment	AU Markt
7D	8.9%	0.6%	1.4%
1Y	10.9%	15.3%	17.7%

Rendement versus industrie: NTI presteerde slechter dan de Australian Medical Equipment -sector, die het afgelopen jaar een rendement van 15.3 % opleverde.

Rendement versus markt: NTI presteerde slechter dan Australian Market, dat het afgelopen jaar een rendement van 17.7 % opleverde.

Prijsvolatiliteit

Is NTI's price volatile compared to industry and market?
NTI volatility
NTI Average Weekly Movement	7.6%
Medical Equipment Industry Average Movement	9.0%
Market Average Movement	8.6%
10% most volatile stocks in AU Market	17.3%
10% least volatile stocks in AU Market	3.4%

Stabiele aandelenkoers: NTI heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 8% ) van NTI is het afgelopen jaar stabiel geweest.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2016	n/a	Peter James Griffiths	www.neurotechinternational.com

Neurotech International Limited, een biofarmaceutisch ontwikkelingsbedrijf in een klinische fase, houdt zich bezig met onderzoek, ontwerp, ontwikkeling en productie van medische hulpmiddelen en oplossingen in Australië. Het bedrijf richt zich op de ontwikkeling en commercialisering van NTI164 voor meerdere pediatrische neurologische aandoeningen; en Mente, een klinisch bewezen thuistherapie gericht op het verbeteren van betrokkenheid en ontspanning bij autistische kinderen met verhoogde delta-band hersenactiviteit. Het bedrijf voert ook medische onderzoeksprojecten uit en ontwikkelt technologische apparaten.

Neurotech International Limited Samenvatting

Hoe verhouden de winst en inkomsten van Neurotech International zich tot de beurswaarde?
NTI fundamentele statistieken
Marktkapitalisatie	AU$63.11m
Inkomsten(TTM)	-AU$5.07m
Inkomsten(TTM)	AU$3.18m

19.9x

P/S-verhouding

-12.4x

Koers/Winstverhouding

Is NTI overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
NTI resultatenrekening (TTM)
Inkomsten	AU$3.18m
Kosten van inkomsten	AU$7.83k
Brutowinst	AU$3.17m
Overige uitgaven	AU$8.24m
Inkomsten	-AU$5.07m

Laatst gerapporteerde inkomsten

Jun 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-0.0049
Brutomarge	99.75%
Nettowinstmarge	-159.54%
Schuld/Eigen Vermogen Verhouding	0%

Hoe presteerde NTI op de lange termijn?

Bekijk historische prestaties en vergelijking

NTI Overzicht aandelen

Beloningen

Risicoanalyse

Neurotech International Limited Concurrenten

ASX:CVB

AU$41.4m

ASX:MX1

AU$39.0m

ASX:CDX

AU$35.3m

ASX:SOM

AU$60.5m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Now 22% overvalued

Now 20% overvalued

Neurotech International Limited, Annual General Meeting, Nov 20, 2024

Full year 2024 earnings released: AU$0.006 loss per share (vs AU$0.01 loss in FY 2023)

Less than half of directors are independent

Neurotech International Limited has completed a Follow-on Equity Offering in the amount of AUD 10 million.

Recent updates

Now 22% overvalued

Now 20% overvalued

Neurotech International Limited, Annual General Meeting, Nov 20, 2024

Full year 2024 earnings released: AU$0.006 loss per share (vs AU$0.01 loss in FY 2023)

Less than half of directors are independent

Neurotech International Limited has completed a Follow-on Equity Offering in the amount of AUD 10 million.

Neurotech International Limited has completed a Follow-on Equity Offering in the amount of AUD 10 million.

Neurotech International Limited to Report Q1, 2024 Results on Oct 27, 2023

Neurotech International Limited, Annual General Meeting, Nov 15, 2023

Full year 2023 earnings released: AU$0.01 loss per share (vs AU$0.005 loss in FY 2022)

New minor risk - Financial data availability

Neurotech International Limited to Report Q4, 2023 Results on Jul 26, 2023

First half 2023 earnings released: AU$0.48 loss per share (vs AU$0.003 loss in 1H 2022)

Neurotech International Limited Announces First Patient Treated in Phase I/II PANDAS/PANS Trial

Neurotech International Limited Announces Approval for Additional Phase I/II ASD Trial Extension

Neurotech International Limited Receives HREC Approval for Phase I/II PANDAS/PANS Clinical Trial

Neurotech International Limited to Report Q3, 2023 Results on Jan 30, 2023

Neurotech International Limited Announces Grant of FDA Pre-IND Meeting for NTI164 in ASD

Neurotech International Limited Announces Passing of Professor Allan Cripps AO, Non-Executive Director

Neurotech International Limited Announces Commencement of Patient Randomisation and First Patient Successfully Treats Under New Phase II/III NTIASD2 Clinical Trial for Children with Autism Spectrum Disorder

Less than half of directors are independent

Neurotech International Limited, Annual General Meeting, Nov 30, 2022

Neurotech International Limited, Annual General Meeting, Nov 23, 2022

Neurotech International Limited Reports Further Significant Clinical Improvement at 20 Weeks for Paediatric Autism Patients Treated with NTI164

Neurotech International Limited Announces New Phase I/II Clinical Trial in Children with PANDAS/PANS

Neurotech International Limited Provides Autism Spectrum Disorder Phase I/II Clinical Trial Update

Less than half of directors are independent

Neurotech International Limited Announces Transition of Alexandra Andrews from Chief Executive Officer to a New Position of Chief Operating Officer

Full year 2022 earnings released: AU$0.005 loss per share (vs AU$0.015 loss in FY 2021)

Neurotech International Limited Announces Currently Finalising a Pivotal Phase II/III Clinical Trial Design to be Conducted in Australia

Neurotech International ORDINARY FULLY PAID to Be Deleted from OTC Equity

Neurotech International Limited Announces Executive Changes

Neurotech International Limited Announces Results with NTI164 in Paediatric ASD

High number of new directors

Neurotech International Limited Announces Important Developments Relating to the Study Protocol Assessing NTI164 in Children with Autism Spectrum Disorder

High number of new directors

Neurotech International Limited Announces Successful Developments Relating to Safety and Tolerability of NTI164 and Key Behavioural Parameters That Impact Autism Spectrum Disorder Patients

Neurotech International Limited Appoints Alexandra Andrews as Chief Executive Officer, Effective 8 March 2022

Neurotech International Limited Announces Nti164 Clinical Program Update

Full year 2021 earnings released: AU$0.015 loss per share (vs AU$0.011 loss in FY 2020)

Neurotech International Limited Announces the Continuation of Its Pre-Clinical Program in Neuro-Inflammatory Disease Models In-Line with Research and Development Pathway

Neurotech International Limited Initiates Phase I/II Open Label Study into Autism

Neurotech International Limited has completed a Follow-on Equity Offering in the amount of AUD 2 million.

Neurotech International Limited Announces Strategic Cultivation Partnership with CannaPacific Limited

Neurotech International Limited Announces the Expansion of Its Exclusive License with Dolce Cann Global Pty Ltd

Neurotech International Limited Provides an Update on Clinical Study Program

Neurotech International Limited has completed a Follow-on Equity Offering in the amount of AUD 2.5 million.

Neurotech International Limited Announces Initiation of Clinical Product Formulation Studies

Neurotech International Limited Announces Transition of Peter Griffiths as CEO

Neurotech International Limited Commences Landmark in Vitro Trials of Unique Cannabis Strains

Full year earnings released - AU$0.011 loss per share

Rendement voor aandeelhouders

Prijsvolatiliteit

Over het bedrijf

Neurotech International Limited Samenvatting

19.9x

-12.4x

Inkomsten en omzet